La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Kyverna Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Kyverna Therapeutics..

Kyverna Therapeutics (NASDAQ:KYTX) Azioni, Catena delle Opzioni

Kyverna Therapeutics

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

KYTX

PSFE

RMBL

I titoli da tenere d&#39;occhio oggi: Home Depot, RumbleOn, Paysafe, Kyverna Therapeutics e XP Inc. nel pre-market.

Pre-market: 5 titoli da monitorare oggi, 13 agosto 2024

Morgan Stanley analyst Michael Cyprys maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Equal-Weight and raises the price target from $43 to $110.

Price Target

Analyst Ratings

HOOD

Morgan Stanley Maintains Equal-Weight on Robinhood Markets, Raises Price Target to $110

Comscore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCOR#NASDAQ">SCOR</a>), a global leader in measuring and analyzing consumer behaviors, today announced a multi-year partnership with HyphaMetrics, a Data-as-a-Service (DaaS) company transforming the media industry's understanding of what the world is watching. Once live, this data partnership and technology integration will expand Comscore's cross-platform measurement capabilities, introducing new CTV program-level reporting and delivering greater granularity to meet the growing demands of the programmatic streaming landscape.
The partnership intends to enhance Comscore's proprietary industry personification methodology by leveraging HyphaMetrics' proprietary ‘Unified Individual Media Metric', a unified view of audience behavior across every monitored screen and streaming platform within a household. This includes deterministic Viewers-per-Viewing-Household data and person-level co-viewing insights across devices. Comscore's personification approach transforms household-level viewing data into a more precise understanding of the individuals behind the screens, bringing new precision to both linear and CTV audience measurement.

SCOR

Comscore Announces Multi-Year Partnership With HyphaMetrics To Launch Person-Level Audience Measurement And CTV Program-Level Reporting

Morgan Stanley analyst Michael Cyprys downgrades Ameriprise Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMP#NYSE">AMP</a>) from Equal-Weight to Underweight and raises the price target from $462 to $530.

Downgrades

Morgan Stanley Downgrades Ameriprise Finl to Underweight, Raises Price Target to $530

Kinder Morgan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMI#NYSE">KMI</a>) will release earnings results for the second quarter, after the <a href="https://www.benzinga.com/quote/KMI/earnings">closing bell on Wednesday, July 16.</a>
Analysts expect the Houston, Texas-based company to report quarterly earnings at 27 cents per share, up from 25 cents per share in the year-ago period. Kinder Morgan projects to report quarterly revenue of $3.75 billion, compared to $3.57 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 16, Kinder Morgan reported first-quarter revenue of $4.24 billion, missing the consensus estimate of $4.08 billion, according to Benzinga Pro. The energy infrastructure company reported adjusted quarterly earnings of 34 cents per share, missing analyst estimates of 35 cents per share.
Kinder Morgan shares gained 1.7% to close at $28.32 on Monday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/kmi/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Barclays analyst Theres Chen maintained an Overweight rating and raised the price target from $31 to $32 on June 23, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Stifel analyst Selman Akyol maintained a Hold rating and raised the price target from $27 to $28 on June 3, 2025. This analyst has an accuracy rate of 71%.</li>
<li>Citigroup analyst Spiro Dounis maintained a Neutral rating and boosted the price target from $25 to $28 on Jan. 29, 2025. This analyst has an accuracy rate of 76%.</li>
<li>Wells Fargo analyst Michael Blum maintained an Overweight rating and raised the price target from $30 to $33 on Jan. 23, 2025. This analyst has an accuracy rate of 66%.</li>
</ul>
Considering buying KMI stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="578" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15051008/image-163-1024x578.png" alt="" class="wp-image-985469" style="width:680px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15051008/image-163-1024x578.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15051008/image-163-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15051008/image-163-768x433.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15051008/image-163.png 1117w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Top Wall Street Forecasters Revamp Kinder Morgan Expectations Ahead Of Q2 Earnings

Cantor Fitzgerald analyst Ross Osborn reiterates Organogenesis Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ORGO#NASDAQ">ORGO</a>) with a Overweight and maintains $7 price target.

Reiteration

ORGO

Cantor Fitzgerald Reiterates Overweight on Organogenesis Holdings, Maintains $7 Price Target

Morgan Stanley analyst Carlos De Alba downgrades Nexa Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEXA#NYSE">NEXA</a>) from Equal-Weight to Underweight and lowers the price target from $7 to $5.

NEXA

Morgan Stanley Downgrades Nexa Res to Underweight, Lowers Price Target to $5

WIIM

SANW

S&W Seed Company shares are trading lower after announcing it will voluntarily delist from the Nasdaq and deregister with the SEC.

<a href="https://www.bloomberg.com/news/articles/2025-07-15/bessent-tells-markets-not-to-worry-about-china-tariff-deadline" title="https://www.bloomberg.com/news/articles/2025-07-15/bessent-tells-markets-not-to-worry-about-china-tariff-deadline">https://www.bloomberg.com/news/articles/2025-07-15/bessent-tells-markets-not-to-worry-about-china-tariff-deadline</a>

Government

Regulations

Politics

General

'Bessent Tells Markets Not To Worry About China Tariff Deadline' - Bloomberg

Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) will release earnings results for the second quarter before the opening <a href="https://www.benzinga.com/quote/MS/earnings">bell on Wednesday, July 16.</a>
Analysts expect the New York-based investment bank to report quarterly earnings at $2.01 per share. That&#8217;s up from $1.82 per share in the year-ago period. Morgan Stanley also projects to report quarterly revenue of $16.04 billion. Compare that to the $15.02 billion it earned the previous year, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On July 8, Morgan Stanley Investment Management, through investment funds managed by Morgan Stanley Infrastructure Partners, agreed to sell its ownership stake in TigerGenCo Red Oak Holdings, LLC to funds managed by Strategic Value Partners.
With the recent buzz around Morgan Stanley, some investors may be eyeing potential gains from the company's dividends too. As of now, Morgan Stanley offers an annual dividend yield of 2.57%, which is a semi-annual dividend amount of 93 cents per share ($3.70 a year). &nbsp;
So, how can investors exploit its dividend yield to pocket a regular $500 monthly?
To earn $500 per month or $6,000 annually from dividends alone, you would need an investment of approximately $233,519 or around 1,622 shares. For a more modest $100 per month or $1,200 per year, you would need $46,646 or around 324 shares.
To calculate: Divide the desired annual income ($6,000 or $1,200) by the dividend ($3.70 in this case). So, $6,000 / $3.70 = 1,622 ($500 per month), and $1,200 / $3.70 = 324 shares ($100 per month).
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
How that works: The dividend yield is computed by dividing the annual dividend payment by the stock&#8217;s current price.
For example, if a stock pays an annual dividend of $2 and is currently priced at $50, the dividend yield would be 4% ($2/$50). However, if the stock price increases to $60, the dividend yield drops to 3.33% ($2/$60). Conversely, if the stock price falls to $40, the dividend yield rises to 5% ($2/$40).
Similarly, changes in the dividend payment can impact the yield. If a company increases its dividend, the yield will also increase, provided the stock price stays the same. Conversely, if the dividend payment decreases, so will the yield.
MS Price Action: Shares of Morgan Stanley gained 1.2% to close at $143.97 on Monday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday"> JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Image: Shutterstock

Long Ideas

Dividends

How To Earn $500 A Month From Morgan Stanley Stock Ahead Of Q2 Earnings

Morgan Stanley analyst Carlos De Alba downgrades Southern Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCCO#NYSE">SCCO</a>) from Equal-Weight to Underweight and raises the price target from $86 to $99.

SCCO

Morgan Stanley Downgrades Southern Copper to Underweight, Raises Price Target to $99

Cantor Fitzgerald analyst Ross Osborn reiterates MiMedx Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDXG#NASDAQ">MDXG</a>) with a Overweight and maintains $11 price target.

MDXG

Cantor Fitzgerald Reiterates Overweight on MiMedx Group, Maintains $11 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul class="wp-block-list">
<li>JP Morgan analyst Stephen Tusa upgraded Otis Worldwide Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OTIS#NYSE">OTIS</a>) from Neutral to Overweight and raised the price target from $101 to $109. Otis Worldwide shares closed at $100.04 on Monday. <a href="https://www.benzinga.com/quote/OTIS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Redburn Atlantic analyst Agnieszka Pustula upgraded Warner Music Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) from Sell to Neutral and announced a $30 price target. Warner Music shares closed at $30.46 on Monday. <a href="https://www.benzinga.com/quote/WMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Noah Hungness upgraded the rating for National Fuel Gas Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NFG#NYSE">NFG</a>) from Underperform to Buy and raised the price target from $85 to $107. National Fuel Gas shares closed at $84.07 on Monday. <a href="https://www.benzinga.com/quote/NFG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Stephen Tusa upgraded APi Group Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APG#NYSE">APG</a>) from Neutral to Overweight and raised the price target from $31 to $42. APi Group shares closed at $34.50 on Monday. <a href="https://www.benzinga.com/quote/APG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Zach Parham upgraded the rating for California Resources Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) from Neutral to Overweight and boosted the price target from $60 to $63. California Resources shares closed at $47.60 on Monday. <a href="https://www.benzinga.com/quote/CRC/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying OTIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/OTIS/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="601" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15084314/image-178-1024x601.png" alt="" class="wp-image-985909" style="width:567px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15084314/image-178-1024x601.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15084314/image-178-300x176.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15084314/image-178-768x451.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/15084314/image-178.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday"> JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo via Shutterstock

Upgrades

OTIS

This Otis Worldwide Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday

Morgan Stanley analyst Carlos De Alba downgrades Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) from Overweight to Equal-Weight and raises the price target from $45 to $54.

Morgan Stanley Downgrades Freeport-McMoRan to Equal-Weight, Raises Price Target to $54

Serina Therapeutics shares are trading higher on possible continued strength after HC Wainwright & Co. initiated coverage on the stock yesterday with a Buy rating and announced a price target of $15.

Morgan Stanley analyst Carlos De Alba downgrades Teck Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TECK#NYSE">TECK</a>) from Overweight to Equal-Weight and raises the price target from $42 to $44.

TECK

Morgan Stanley Downgrades Teck Resources to Equal-Weight, Raises Price Target to $44

Morgan Stanley analyst Adam Kramer initiates coverage on Sun Communities (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUI#NYSE">SUI</a>) with a Equal-Weight rating and announces Price Target of $135.

Initiation

Morgan Stanley Initiates Coverage On Sun Communities with Equal-Weight Rating, Announces Price Target of $135

Nova Materials shares are trading lower after the company announced it has priced a $11.1 million public offering.

Cantor Fitzgerald analyst Derek Soderberg initiates coverage on Oklo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) with a Overweight rating and announces Price Target of $73.

OKLO

Cantor Fitzgerald Initiates Coverage On Oklo with Overweight Rating, Announces Price Target of $73

In a world where technology and resources shape economic power, recent strategic moves by major companies reflect broader market shifts and <a href="https://www.benzinga.com/topic/wall-street">growing global challenges.</a>
On <a href="https://www.cnbc.com/video/2025/07/14/final-trades-lockheed-martin-netflix-ishares-u-s-industrials-etf-and-check-point.html">CNBC's </a>&#8220;Halftime Report Final Trades,&#8221; Jim Lebenthal, chief equity strategist at Cerity Partners, named Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) as his <a href="https://www.benzinga.com/markets/equities/25/07/46390158/lockheed-martin-in-talks-to-tap-untouched-pacific-mining-licenses-amid-global-mineral-push">final trade</a>.
Lockheed Martin is reportedly in talks with mining companies to enable the development of its licensed areas on the Pacific seabed. The move comes as global competition for critical minerals intensifies.
Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, said Netflix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) will continue going higher despite a couple of analysts downgrading the stock over the last couple of weeks.
Lending support to his choice, Piper Sandler analyst Matt Farrell maintained a Netflix rating of Overweight on Friday and raised the price target from $1,150 to $1,400. In contrast, Needham analyst Laura Martin maintained a Buy rating and boosted the price target from $1,126 to $1,500.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Shannon Saccocia, chief investment officer of NB Private Wealth, picked iShares U.S. Industrials ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYJ#NYSE">IYJ</a>) as her final trade.
Joseph M. Terranova, senior managing director for Virtus Investment Partners, said he likes Check Point Software Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHKP#NASDAQ">CHKP</a>).
On the earnings front, Check Point Software will release its financial results for the second quarter on Wednesday, July 30. Analysts expect the company to report quarterly earnings at $2.36 per share on revenue of $662.11 million.
Price Action:
<ul class="wp-block-list">
<li>Lockheed Martin shares gained 1.3% to close at $473.57 on Monday.</li>
<li>Netflix rose 1.4% to close at $1,261.95 during the session.</li>
<li>iShares U.S. Industrials ETF gained 0.5% on Monday.</li>
<li>Check Point Software shares gained 2.4% to close at $220.68 during the session.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/07/46408189/jpmorgan-wells-fargo-and-3-stocks-to-watch-heading-into-tuesday">JPMorgan, Wells Fargo And 3 Stocks To Watch Heading Into Tuesday</a></li>
</ul>
Photo: Shutterstock

Media

CHKP

iShares Trust Dow Jones US Industrial Sector Index Fund

NFLX

Netflix, Lockheed Martin, Check Point Software And More On CNBC's 'Final Trades'

Morgan Stanley analyst Adam Kramer initiates coverage on Equity Lifestyle Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ELS#NYSE">ELS</a>) with a Equal-Weight rating and announces Price Target of $67.5.

Morgan Stanley Initiates Coverage On Equity Lifestyle Props with Equal-Weight Rating, Announces Price Target of $67.5

Legal

Press Releases

Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

ALERT: Grabar Law Office Investigates Claims for Long-Term Shareholders of Holley Inc. (NYSE: HLLY); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); and Virtu Financial, Inc. (NASDAQ: VIRT)

Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf

Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

KYVERNA ALERT: Bragar Eagel & Squire, P.C. is Investigating Kyverna Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Comments

Kyverna Therapeutics

Kyverna Therapeutics (KYTX) Opzioni

Kyverna Therapeutics (NASDAQ:KYTX) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO